The bentiromide test for pancreatic exocrine insufficiency

Area of Science:

• Gastroenterology
• Diagnostic Medicine
• Biochemistry

Background:

• Pancreatic exocrine insufficiency (PEI) is a condition affecting digestion.
• Accurate diagnostic methods for PEI are crucial for effective management.
• The bentiromide test offers a new approach to assessing pancreatic function.

Purpose of the Study:

• To evaluate the efficacy of the bentiromide test for diagnosing pancreatic exocrine insufficiency.
• To determine optimal dosage and collection periods for the bentiromide test.
• To assess the safety and practicality of the bentiromide test in clinical settings.

Main Methods:

• The bentiromide test measures chymotrypsin activity in urine.
• Studies included adult patients with chronic pancreatic disease and children with cystic fibrosis.
• Optimal parameters identified: 500-mg dose and a 6-hour urine collection period.

Main Results:

• The 500-mg bentiromide test effectively differentiates patients with chronic pancreatic disease from healthy controls.
• The test demonstrated a high degree of accuracy in identifying pancreatic exocrine insufficiency.
• Virtually no side effects were reported with the 500-mg dosage.

Conclusions:

• The bentiromide test is a reliable, safe, and simple outpatient method for diagnosing pancreatic exocrine insufficiency.
• This test confirms chymotrypsin function, aiding in the diagnosis of PEI.
• The FDA approval signifies its clinical utility in gastroenterology.